Samaritan to Present Its Drugs and Diagnostics for Partnering at BIO 2006 Annual International Conference

Samaritan Pharmaceuticals Inc. (AMEX:LIV):

   --  PII/III HIV Oral Entry Inhibitor Drug

   --  Cardiovascular Drug SP-1000

   --  Alzheimer's Drug SP-233

   --  Alzheimer's Blood Diagnostic

   --  Breast Cancer Diagnostic

   --  Alzheimer's Animal Model

   Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of
innovative drugs, announced today, it is taking the opportunity to
present its pipeline of innovative drugs at Bio 2006 in Chicago April
9th thru April 12, 2006.
   Samaritan will seek to out-license its promising drugs and
diagnostics; and at the same time focus on in-licensing opportunities.
Samaritan has established its own marketing and sales arm in Europe,
which focuses on in-licensing niche drugs from other pharmaceutical
companies, to sell their products in Eastern Europe, creating a
revenue source for Samaritan.
   BIO, the Biotechnology Industry Organization, is the industry's
largest trade organization bringing together over 18 thousand people
from around the world, representing every aspect of the biotech
community.
   Dr. Greeson, CEO of Samaritan stated, "BIO is the best venue for
us to discuss our out-licensing opportunities with key executives from
major pharmaceuticals. Everyone in the partnering section of the
conference focuses on deals, and we normally have every half hour time
slot filled for the three days by the time we get there. In addition,
this year a main priority for us is to in-license other company's
drugs, to market in the mostly overlooked South East and Central
Europe, mainly Greece, Bulgaria, Romania, Croatia, Serbia, Turkey,
Slovenia, Slovakia, Czech Republic, Poland and Hungary."

   Samaritan Pharmaceuticals: "We LIV....to Save Lives."

   Samaritan is a small-cap Biotech, driven to discover, develop, and
commercialize, innovative therapeutics' for AIDS, Alzheimer's, Cancer
and Heart disease. Look at www.samaritanpharma.com. Please register on
Website so we can notify you of upcoming conference calls, news and
events.

   Disclaimer

   The company disclaims any information that is created by an
outside party and endorses only information that is communicated by
its press releases, filings and Website. This news release contains
forward-looking statements that reflect management's current beliefs
about the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development and
regulatory review. There are no guarantees that products will prove to
be commercially successful. For additional information about the
factors that affect the company's business, please read the company's
latest Form 10-K filed April 15, 2005. The company undertakes no duty
to update forward-looking statements.